Oscient Pharmaceuticals Corp. (OSCI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: sjemmeri	8/1/2006 9:39:43 AM
	of 1154

Oscient, Pfizer Get OK To Market Antibiotic In Mexico>OSCI Dow Jones Newswires - August 01, 2006 9:03 AM ET Related Quotes Symbol Last Chg OSCI Trade 0.96 +0.079 PFE Trade 26.14 +0.15 Real time quote. DOW JONES NEWSWIRES Oscient Pharmaceuticals Corp. (OSCI) said its antibiotic Factive received approval from the Ministry of Health in Mexico to be marketed as Factive-5 for the five-day treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis. The Waltham, Mass., pharmaceutical company said Pfizer Inc.'s (PFE) Mexico-based Pfizer S.A. de C.V. sub-licensed the rights to develop and market Factive in Mexico in February. The regulatory approval resulted in an undisclosed milestone payment to Oscient from Pfizer. Oscient also will receive royalties on future sales of the drug in Mexico. Pfizer prepared the regulatory filing based on the drug's clinical trial dossier and expects to launch Factive-5 in the coming weeks. -Adam Kuczynski; 201-938-5400; AskNewswires@dowjones.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next